RESEARCH ARTICLE

Platelet–Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer

Yuka Asano¹, Shinichiro Kashiwagi¹*, Naoyoshi Onoda¹*, Satoru Noda¹, Hidemi Kawajiri¹, Tsutomu Takashima¹, Masahiko Ohsawa², Seiichi Kitagawa³, Kosei Hirakawa¹

¹ Department of Surgical Oncology; Osaka City University Graduate School of Medicine, Osaka, Japan, ² Department of Diagnostic Pathology; Osaka City University Graduate School of Medicine, Osaka, Japan, ³ Department of Physiology, Osaka City University Graduate School of Medicine, Osaka, Japan

* These authors contributed equally to this work.

Abstract

Background

The peripheral blood platelet–lymphocyte ratio (PLR) has been proposed as an indicator for evaluating systemic inflammatory responses in cancer-bearing patients. While some reports suggest a correlation between PLR and prognosis, few studies have examined the relationship between PLR and sensitivity to chemotherapy. We conducted a study on whether PLR could serve as a predictor of the therapeutic effects of neoadjuvant chemotherapy (NAC).

Methods

PLR was evaluated in 177 breast cancer patients treated with the NAC 5-fluorouracil, epirubicin and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between PLR and prognosis, and between PLR and the efficacy of NAC, were evaluated retrospectively.

Results

The low PLR group had significantly more patients > 56 years old (p = 0.001) and postmenopausal women (p = 0.001) than the high PLR group. The low PLR group also had a higher pathologic complete response (pCR) rate (p = 0.019). On examining the correlation with prognosis, the low-PLR group was found to have significantly longer disease-free survival (p = 0.004) and overall survival (p = 0.032) than the high PLR group. Multivariate analysis also revealed that lymph node metastasis (p = 0.043, hazard ratio = 4.40) and a high PLR (p = 0.005, hazard ratio = 2.84) were independent, unfavorable prognostic factors.
Conclusions

For patients with breast cancer treated with NAC, a low PLR indicated high chemotherapy sensitivity, suggesting that PLR could serve as a predictive marker of the therapeutic effect of NAC.

Introduction

In recent years, the peripheral blood neutrophil–lymphocyte ratio (NLR) and the platelet–lymphocyte ratio (PLR) have been proposed as indicators for evaluating systemic inflammatory responses in cancer-bearing patients and have shown utility as predictive markers for prognosis [1–7]. Neoadjuvant chemotherapy (NAC) increases the rate of breast-conserving surgery and reduces the risk of postoperative recurrence in patients with resectable breast cancer [8–11]. The main purpose of NAC is its use in building a treatment strategy based on confirmed therapeutic effects and their outcomes through reducing tumor size and improving breast-conservation rates [8, 12, 13]. To date, we have reported on the usefulness of NLR as a predictor of the effect of NAC in triple-negative breast cancer [6, 7].

Meanwhile, the PLR in preoperative peripheral blood reportedly represents an independent prognostic factor in breast cancer [6, 7]. A high PLR in many types of cancer, including gastric [14], colorectal [15–17], pancreatic [18] and ovarian [19, 20], is said to indicate a poor prognosis. Platelets are cells containing the largest quantity of growth factors, such as platelet-derived growth factor (PDGF) [21–25], transforming growth factor (TGF)-β [26, 27] and platelet-derived endothelial cell growth factor (PD-ECGF) [28–30]. These platelet-derived growth factors are often produced in large quantities by cancer cells and contribute to cancer growth and histology [25, 26]. Lymphocytes are known to be responsible for the immune response against tumors, suggesting that PLR may be related to prognosis and chemotherapy sensitivity. While some reports suggest a correlation between PLR and prognosis [6, 7, 15, 18, 19], few studies have examined the relationship between PLR and sensitivity to chemotherapy. We conducted a study on whether PLR could serve as a predictor of the therapeutic effects of NAC.

Materials and Methods

Patient Background

As described in detail previously [31], a total of 177 patients with resectable, early-stage breast cancer diagnosed as stage IIA (T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0) or IIIA (T1-2, N2, M0 or T3, N1-2, M0) were treated with NAC between 2007 and 2013. Our previous report also used the same patient population as the present study, but it was a study of the significance of androgen receptor expression [31]. Tumor stage and T and N factors were stratified based on the TNM Classification of Malignant Tumors, Union for International Cancer Control (UICC) Seventh Edition [32]. Breast cancer was confirmed histologically using core needle biopsies and staged with systemic imaging studies using computed tomography (CT), ultrasonography (US) and bone scintigraphy. Breast cancer was classified into subtypes according to the immunohistochemical expression of the estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (HER2), and Ki67. Cutoffs for ER and PR positivity were both >0% positive tumor cells with nuclear staining. Tumors with 3+ HER2 on immunohistochemical staining were considered to show HER2 overexpression; tumors with 2+ HER2 were further analyzed using fluorescence in situ hybridization; and
those with HER2/CEP17 ≥2.0 were also considered to exhibit HER2 overexpression. A Ki67-labeling index ≥14% tumor cells with nuclear staining was determined to be positive.

All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m² fluorouracil, 100 mg/m² epirubicin and 500 mg/m² cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m² paclitaxel administered weekly [33, 34]. Forty-five patients had HER2-positive breast cancer and were additionally administered weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab during paclitaxel treatment [35]. All patients underwent chemotherapy as outpatients.

Therapeutic anti-tumor effects were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria [36]. Pathologic complete response (pCR) was defined as the complete disappearance of the invasive components of the lesion with or without intraductal components, including in the lymph nodes. Patients underwent mastectomy or breast-conserving surgery after NAC. All patients who underwent breast-conserving surgery were administered postoperative radiotherapy to the remnant breast. The postoperative adjuvant therapy performed endocrine therapy and/or anti-HER2 treatment depending on every case.

Overall survival (OS) time was defined as the period from the initiation of NAC to the time of death from any cause. Disease-free survival (DFS) was defined as freedom from all local, loco-regional and distant recurrences. All patients were followed up with a physical examination every 3 months, US every 6 months, and CT and bone scintigraphy annually. The median follow-up period for the assessment of OS was 3.4 years (range, 0.6–6.0 years) and for DFS, it was 3.1 years (range, 0.1–6.0 years).

Ethics Statement
This research conformed to the provisions of the 1995 Declaration of Helsinki. All patients were informed of the investigational nature of this study and provided their written informed consent. The Ethics Committee of Osaka City University approved the study protocol (#926).

Blood Sample Analysis
Peripheral blood was obtained at the time of diagnosis, before NAC. The number of blood cells was determined using a hemocytometer. Percentages of different cell types were determined using a Coulter LH 750 Hematology Analyzer (Beckman Coulter, Brea, CA, USA). PLR was calculated from the preoperative blood sample by dividing the absolute platelet count by the absolute lymphocyte count. On the basis of previous studies, a PLR value of 150.0 was used as the cutoff value to discriminate between high-PLR (≥150.0) and low-PLR (<150.0) [37].

Statistical Analysis
Statistical analysis was performed using the SPSS version 19.0 statistical software package (IBM, Armonk, NY, USA). We examined associations between PLR and clinicopathologic variables using the chi-squared test (or Fisher’s exact test when necessary). The association with survival was analysed using the Kaplan–Meier plot and log-rank test. The Cox proportional hazards model was used to compute univariable and multivariable hazard ratios (HR) for the study parameters with 95% confidence intervals (c.i.), and used in a backward stepwise method for variable selection in multivariate analysis. In all of the tests, a p-value of less than 0.05 was considered statistically significant. Cut-off values for different biomarkers included in this study were chosen before statistical analysis.
Results

In this study, NAC was administered to 177 patients with early-stage breast cancer. The therapeutic effect was pCR in 67 patients (37.9%) and non-pCR in 110 patients (62.1%) (Table 1). PLR was determined in every sample and ranged from 40.5–463.0 (mean, 148.6; median, 135.2; standard deviation, 66.6). The high-PLR group comprised 67 patients (37.9%) and the low-PLR group comprised 110 patients (62.1%). Patients who received NAC were sorted into high- and low-PLR groups and the clinicopathological characteristics of each group were examined. The low-PLR group had significantly more patients > 56 years old (the median value of age) (p = 0.001) and postmenopausal women (p = 0.001) than the high-PLR group. The low-PLR group also had a higher pCR rate (p = 0.019) (Table 2). However, no correlation was seen with other clinicopathological factors, including subtype.

On examining the correlation with prognosis, the low-PLR group was found to have significantly longer DFS (p = 0.004, log-rank) (Fig 1A) and OS (p = 0.032, log-rank) (Fig 1B) than the high PLR group. Univariate analysis revealed that lymph node metastasis (p = 0.049, hazard ratio = 4.23) and a high PLR (p = 0.006, hazard ratio = 2.77) were unfavorable prognostic factors (Fig 2). Moreover, multivariate analysis also revealed that lymph node metastasis (p = 0.043, hazard ratio = 4.40) and a high PLR (p = 0.005, hazard ratio = 2.84) were independent, unfavorable prognostic factors (Table 3).

Discussion

In the past it was believed that cancer cells could autonomously proliferate and survive because of a variety of genetic abnormalities, but recently it has become clear that the peripheral environment (tumor microenvironment) greatly affects cancer cells and contributes to the formation of characteristics particular to cancer. Therefore, monitoring the host's tumor microenvironment is believed to play a key role in predicting therapeutic efficacy and prognosis. Systematic inflammatory indicators, such as NLR or PLR, have been reported as monitoring the host's tumor microenvironment. [14,37,38].

The cell proliferation process, particularly autonomous proliferation, is important to elucidate the mechanisms of carcinogenesis, as growth factors and their receptors are closely related to cancer genes [24]. Platelet-derived growth factors include PDGF [21, 22], TGF-β [26, 27] and PD-ECGF [26, 29, 38], and are involved in the repair and regeneration of tissue. PDGF has a similar structure to the protein that makes up the sis cancer gene, and the tyrosine kinase structure seen in PDGF receptors is found in some cancer genes. Moreover, administration of PDGF induces cancer genes such as myc and fos, which are present in the cell nucleus. This

Table 1. Clinical response rate and pathological response rate to neoadjuvant chemotherapy.

| pathologic response | all breast cancers (n = 177) | TNBC (n = 61, 34.5%) | HER2BC (n = 36, 20.3%) | HRBC (n = 80, 45.2%) |
|---------------------|-----------------------------|----------------------|-----------------------|----------------------|
| pCR: pathological complete response | 67 (37.9%) | 28 (45.9%) | 18 (50.0%) | 21 (26.3%) |
| non-pCR: non-pathological complete response | 110 (62.1%) | 33 (54.1%) | 18 (44.7%) | 59 (63.7%) |
| PR: partial response | 84 (47.5%) | 21 (34.4%) | 15 (41.7%) | 48 (60.0%) |
| SD: stable disease | 19 (10.7%) | 8 (13.1%) | 3 (8.3%) | 8 (10.0%) |
| PD: progressive disease | 7 (3.9%) | 4 (6.6%) | 0 (0.0%) | 3 (3.7%) |
| RR (CR+PR): response rate | 151 (85.3%) | 49 (80.3%) | 33 (91.7%) | 69 (86.3%) |

TNBC, triple-negative breast cancer. HER2BC, human epidermal growth factor receptor 2-enriched breast cancer. HRBC, hormone receptor-positive breast cancer. CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease.

doi:10.1371/journal.pone.0153459.t001
suggests that abnormalities that occur in the growth factor activation process are linked to the canceration of cells [25]. TGF-β works to inhibit cancer through cytostatic activity in the early stages of carcinogenesis; however, it conversely works to promote cancer in the later stages as the cancer develops [26].

Table 2. Correlation between clinicopathological features and platelet–lymphocyte ratio in 177 all breast cancers.

| Parameters                  | PLR (n = 177) | p value |
|-----------------------------|---------------|---------|
|                             | High (n = 67) | Low (n = 110) |
| Age at operation            |               |         |
| ≤56                         | 44 (65.7%)    | 43 (39.1%) | 0.001 |
| >56                         | 23 (34.3%)    | 67 (60.9%) |         |
| Menopause                   |               |         |
| Negative                    | 38 (56.7%)    | 34 (30.9%) |         |
| Positive                    | 29 (43.3%)    | 76 (69.1%) |         |
| Tumor size                  |               |         |
| ≤2 cm                       | 8 (11.9%)     | 16 (14.5%) |         |
| >2 cm                       | 59 (88.1%)    | 94 (85.5%) |         |
| Lymph node status           |               |         |
| Negative                    | 17 (25.4%)    | 24 (21.8%) |         |
| Positive                    | 50 (74.6%)    | 86 (78.2%) | 0.587 |
| Nuclear grade               |               |         |
| 1, 2                        | 53 (79.1%)    | 84 (76.4%) |         |
| 3                           | 14 (20.9%)    | 26 (23.6%) | 0.672 |
| Ki67                        |               |         |
| ≤14%                        | 32 (47.8%)    | 42 (38.2%) |         |
| >14%                        | 35 (52.2%)    | 68 (61.8%) | 0.210 |
| Intrinsic subtype           |               |         |
| TNBC                        | 25 (37.3%)    | 36 (32.7%) |         |
| non-TNBC                    | 42 (62.7%)    | 74 (67.3%) | 0.533 |
| Pathological response       |               |         |
| pCR                         | 18 (26.9%)    | 49 (44.5%) |         |
| non-pCR                     | 49 (73.1%)    | 61 (55.5%) | 0.019 |

PLR, platelet–lymphocyte ratio. TNBC, triple-negative breast cancer. pCR, pathologic complete response.

doi:10.1371/journal.pone.0153459.t002

Fig 1. Examination of the correlation with prognosis. The low-PLR group was found to have significantly longer disease-free survival (p = 0.004, log-rank) (A) and overall survival (p = 0.032, log-rank) (B) than the high PLR group.

doi:10.1371/journal.pone.0153459.g001
Platelet-derived growth factors are frequently created in large quantities by cancer cells and have an effect on the histology of cancer [25, 26, 38]. They have been found to contribute to metastasis, invasion and growth of the primary tumor. Peripheral blood platelet count may thus be an indicator of tumor activity. Meanwhile, lymphocytes are responsible for the immune response to tumor growth, and peripheral blood lymphocyte count is thought to be an indicator of tumor suppression. This would suggest that patients in a low-PLR group, with a low platelet count and high lymphocyte count, exhibit high antitumor activity, which would be

Fig 2. Forest plots. Univariate analysis revealed that absence of lymph node metastasis and a low PLR were good prognostic factors.

doi:10.1371/journal.pone.0153459.g002

Table 3. Univariable and multivariable analysis with respect to disease-free survival in breast cancer.

| Parameter                        | Univariable analysis | Multivariable analysis |
|----------------------------------|----------------------|------------------------|
|                                  | Hazard ratio | 95% c.i. | p value | Hazard ratio | 95% c.i. | p value |
| Tumor size (cm)                  |             |          |         |             |          |         |
| <2 vs >2                         | 1.06        | 0.37–3.05| 0.911   |             |          |         |
| Menopause                        |             |          |         |             |          |         |
| Negative vs Positive             | 0.84        | 0.41–1.73| 0.637   |             |          |         |
| Hormone receptor                 |             |          |         |             |          |         |
| Negative vs Positive             | 1.05        | 0.51–2.16| 0.886   |             |          |         |
| HER2                             |             |          |         |             |          |         |
| Negative vs Positive             | 0.695       | 0.27–1.82| 0.459   |             |          |         |
| Nuclear grade                    |             |          |         |             |          |         |
| 1–2 vs 3                         | 1.03        | 0.44–2.39| 0.954   |             |          |         |
| Ki67 (%)                         |             |          |         |             |          |         |
| ≤14 vs >14                       | 0.65        | 0.32–1.33| 0.238   |             |          |         |
| Pathological response            |             |          |         |             |          |         |
| pCR vs non-pCR                   | 0.61        | 0.28–1.34| 0.217   | 0.75        | 0.34–1.66| 0.475   |
| Lymph node status                |             |          |         |             |          |         |
| Negative vs Positive             | 4.23        | 1.01–17.78| 0.049  | 4.40        | 1.05–18.48| 0.043   |
| PLR                              |             |          |         |             |          |         |
| High vs Low                      | 2.77        | 1.33–5.76| 0.006   | 2.84        | 1.37–5.91| 0.005   |

c.i., confidence interval. HER2, human epidermal growth factor receptor 2. pCR, pathological complete response. PLR, platelet–lymphocyte ratio.

doi:10.1371/journal.pone.0153459.t003
correlated with a good prognosis and chemotherapy sensitivity. The patients in the low-PLR group in the present study showed a correlation between PLR and the pCR rate, which was an independent, good prognostic factor.

The mechanism whereby PLR and chemotherapy sensitivity are correlated is thought to occur as follows. Platelets are cells that contain the largest quantity of growth factors, and platelet count is an indicator of cancer activity. A low platelet count suggests cancer with low activity. Chemotherapy promotes myelosuppression and lowers the platelet count. Furthermore, chemotherapy increases lymphocyte count by activating the immune response. This is thought to relatively lower the PLR and enhance the antitumor effects.

We have reported on the usefulness of NLR as a predictor of the effect of NAC in triple-negative breast cancer [6, 7]; however, no correlation was seen between PLR and NAC sensitivity with subtype. NLR is useful as an effective predictive marker in a high lymphocyte activity subtype such as triple-negative breast cancer. On the other hand, PLR was not useful as an effect predictive marker according to subtype, because of growth factor participation. The indication criteria of NAC should be decided by progress degree and intrinsic subtype. However, the high-PLR group that an effect cannot expect so much may become an adjuvant biomarker.

Conclusions

In NAC treatment of breast cancer, a low PLR indicated high chemotherapy sensitivity, suggesting that PLR could serve as a predictive marker of the therapeutic effect of NAC.

Acknowledgments

We thank Yayoi Matsukiyo and Tomomi Ohkawa (Department of Surgical Oncology, Osaka City University Graduate School of Medicine) for helpful advice regarding data management.

Author Contributions

Conceived and designed the experiments: YA SHK. Performed the experiments: NO SN HK TT. Analyzed the data: YA SHK. Contributed reagents/materials/analysis tools: SEK KH. Wrote the paper: YA SHK. Helped with data collection and manuscript preparation: MO.

References

1. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013; 30(1):432. Epub 2013/01/04.: doi: 10.1007/s12032-012-0432-4 PMID: 23283648.

2. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013; 16(1):55–9. Epub 2013/04/18.: doi: 10.4048/jbc.2013.16.1.55 PMID: 23593082; PubMed Central PMCID: PMC3625770.

3. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012; 19(1):217–24. Epub 2011/06/04.: doi: 10.1245/s10434-011-1814-0 PMID: 21638095.

4. Malletzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014; 21(12):3938–46. Epub 2014/05/29.: doi: 10.1245/s10434-014-3815-2 PMID: 24866438.

5. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):djv124. Epub 2014/05/31.: doi: 10.1093/jnci/djv124 djv124 [pii]. PMID: 24875653.

6. Krenn-Pilko S, Langsenlehner U, Thurmer EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014; 110(10):2524–30. Epub 2014/03/29.: doi: 10.1038/bjc.2014.163 bjc2014163 [pii]. PMID: 24875363; PubMed Central PMCID: PMC4021515.
7. Seretis C, Seretis F, Lagoudianakis E, Politou M, Gemenetzis G, Salemis NS. Enhancing the accuracy of platelet to lymphocyte ratio after adjustment for large platelet count: a pilot study in breast cancer patients. Int J Surg Oncol. 2012; 2012:653608. Epub 2013/01/11.: doi: 10.1155/2012/653608 PMID: 23304480; PubMed Central PMCID: PMC3532869.

8. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;(30):96–102. Epub 2002/01/05. PMID: 1173300.

9. van der Hage JA, van de Velde CJ, Juliën JP, Tubiana-Hulin M, Vandooren M, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19(22):4224–37. Epub 2001/11/16. PMID: 11709566.

10. Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110. Epub 2007/09/25.: doi: 10.1186/bcr1755 PMID: 17886189; PubMed Central PMCID: PMC2242653.

11. Sachelarie I, Grossbard ML, Chadha M, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006; 11(6):574–89. Epub 2006/06/24.: doi: 10.1634/theoncologist.11-6-574 PMID: 16794237.

12. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21(22):4165–74. Epub 2003/10/16.: doi: 10.1200/JCO.2003.12.005 JCO.2003.12.005 [pii]. PMID: 14558982.

13. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976–83. Epub 2003/03/15. PMID: 12637460.

14. Aliustaoglu M, Bilici A, Ustaalsoyoglu BB, Konya V, Gucun M, Seker M, et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol. 2010; 27(4):1060–5. Epub 2009/10/23.: doi: 10.1007/s12032-009-9335-4 PMID: 19847679.

15. Stotz M, Pichler M, Absenger G, Szkandera J, Armingier M, Schabert-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014; 110(2):435–40. Epub 2013/12/21.: doi: 10.1038/bjc.2013.785 bjc2013785 [pii]. PMID: 24357796; PubMed Central PMCID: PMC3899781.

16. Kemal Y, Yucel I, Ezik K, Demirag B, Yilmaz B, Teker F, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev. 2014; 15(6):2651–4. Epub 2014/04/26. PMID: 24761879.

17. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97(9):1266–70. Epub 2007/10/10. PMID: 17923866; PubMed Central PMCID: PMC2360467.

18. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197(4):466–72. Epub 2008/07/22.: doi: 10.1016/j.amjsurg.2007.12.057 S0002-9610(08)00344-9 [pii]. PMID: 18639229.

19. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaprapcharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012; 23(4):265–73. Epub 2012/10/25.: doi: 10.3802/jgo.2012.23.4.265 PMID: 23094130; PubMed Central PMCID: PMC3469862.

20. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011; 13(7):499–503. Epub 2011/07/22.: doi: 10.1007/s12094-011-0687-9 CLAT484 [pii]. PMID: 21775277.

21. Heldin CH, Westermark B, Wasteson A. Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci U S A. 1979; 76(6):3722–6. Epub 1979/08/01. PMID: 291037; PubMed Central PMCID: PMC383905.

22. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature. 1986; 320(6064):695–9. Epub 1986/04/24.: doi: 10.1038/320695a0 PMID: 3754619.

23. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990; 248(4958):1009–12. Epub 1990/05/25. PMID: 2343305.
24. Heldin CH, Westermark B. Growth factors: mechanism of action and relation to oncogenes. Cell. 1984; 37(1):9–20. Epub 1984/05/01. doi: 10.1016/0092-8674(84)90296-4 [pii]. PMID: 6373015.

25. Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990; 1(8):555–66. Epub 1990/07/01. PMID: 1964089; PubMed Central PMCID: PMC361590.

26. Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Olofsson A, et al. Latent forms of TGF-beta: structure and biology. Ann N Y Acad Sci. 1990; 593:51–8. Epub 1990/01/01. PMID: 2375598.

27. Sporn MB, Roberts AB. Transforming growth factor-beta. Multiple actions and potential clinical applications. JAMA. 1989; 262(7):938–41. Epub 1989/08/18. PMID: 2666683.

28. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem. 1987; 262(9):4098–103. Epub 1987/03/25. PMID: 3549724.

29. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989; 338(6216):557–62. Epub 1989/04/13. doi: 10.1038/338557a0 PMID: 2467210.

30. Heldin NE, Usuki K, Bergh J, Westermark B, Heldin CH. Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. Br J Cancer. 1993; 68(4):708–11. Epub 1993/10/01. PMID: 8398697; PubMed Central PMCID: PMC1966610.

31. Asano Y, Kashiwagi S, Onoda N, Kurata K, Morisaki T, Noda S, et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer. 2016; 114(1):14–20. doi: 10.1038/bjc.2015.434 PMID: 26757422; PubMed Central PMCID: PMC4716546.

32. Singletry SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003; 98(12):2740–1. Epub 2003/12/12. doi: 10.1002/cncr.11865 PMID: 14669301.

33. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3):188–94. Epub 2005/02/03. doi: 10.1093/jnci/dji021 PMID: 15687361.

34. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;(2):CD005002. Epub 2007/04/20. doi: 10.1002/14651858.CD005002.pub2 PMID: 17443564.

35. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13(1):228–33. Epub 2007/01/04. doi: 10.1158/1078-0432.CCR-06-1345 PMID: 17200359.

36. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228–47. Epub 2008/12/23. doi: 10.1016/j.ejca.2008.10.026 S0959-8049(08)00873-3 [pii]. PMID: 19097774.

37. Chen C, Sun P, Dai QS, Weng HW, Li HP, Ye S. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma. PLoS One. 2014; 9(11): e112581. Epub 2014/11/14. doi: 10.1371/journal.pone.0112581 PONE-D-14-29944 [pii]. PMID: 25393117; PubMed Central PMCID: PMC4230992.

38. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 1995; 64(2):79–82. Epub 1995/04/21. PMID: 7542228.